🚀 VC round data is live in beta, check it out!
DexCom Valuation Multiples
Discover revenue and EBITDA valuation multiples for DexCom and similar public comparables like Philips, Mettler Toledo, Waters, Steris and more.
DexCom Overview
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Founded
1999
HQ
Employees
11.1K
Website
Financials (LTM)
EV
$28B
DexCom Financials
DexCom reported last 12-month revenue of $5B and EBITDA of $1B.
In the same LTM period, DexCom generated $3B in gross profit, $1B in EBITDA, and $867M in net income.
Revenue (LTM)
DexCom P&L
In the most recent fiscal year, DexCom reported revenue of $5B and EBITDA of $1B.
DexCom expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $867M | XXX | $836M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | — | — | $323M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
DexCom Stock Performance
DexCom has current market cap of $28B, and enterprise value of $28B.
Market Cap Evolution
DexCom's stock price is $73.78.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28B | $28B | 0.0% | XXX | XXX | XXX | $2.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDexCom Valuation Multiples
DexCom trades at 5.8x EV/Revenue multiple, and 19.6x EV/EBITDA.
EV / Revenue (LTM)
DexCom Financial Valuation Multiples
As of April 5, 2026, DexCom has market cap of $28B and EV of $28B.
Equity research analysts estimate DexCom's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DexCom has a P/E ratio of 32.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28B | XXX | $28B | XXX | XXX | XXX |
| EV (current) | $28B | XXX | $28B | XXX | XXX | XXX |
| EV/Revenue | 5.8x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | 19.6x | XXX | 20.5x | XXX | XXX | XXX |
| EV/EBIT | 27.1x | XXX | 28.7x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | 9.9x | XXX | XXX | XXX |
| P/E | 32.8x | XXX | 34.0x | XXX | XXX | XXX |
| EV/FCF | 21.0x | XXX | 19.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DexCom Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
DexCom Margins & Growth Rates
DexCom's revenue in the last 12 month grew by 12%.
DexCom's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
DexCom's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DexCom's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
DexCom Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
DexCom Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Mettler Toledo | XXX | XXX | XXX | XXX | XXX | XXX |
| Waters | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| Mindray | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DexCom M&A Activity
DexCom acquired XXX companies to date.
Last acquisition by DexCom was on XXXXXXXX, XXXXX. DexCom acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by DexCom
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDexCom Investment Activity
DexCom invested in XXX companies to date.
DexCom made its latest investment on XXXXXXXX, XXXXX. DexCom invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by DexCom
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DexCom
| When was DexCom founded? | DexCom was founded in 1999. |
| Where is DexCom headquartered? | DexCom is headquartered in United States. |
| How many employees does DexCom have? | As of today, DexCom has over 11K employees. |
| Who is the CEO of DexCom? | DexCom's CEO is Jacob S. Leach. |
| Is DexCom publicly listed? | Yes, DexCom is a public company listed on Nasdaq. |
| What is the stock symbol of DexCom? | DexCom trades under DXCM ticker. |
| When did DexCom go public? | DexCom went public in 2005. |
| Who are competitors of DexCom? | DexCom main competitors are Philips, Mettler Toledo, Waters, Steris. |
| What is the current market cap of DexCom? | DexCom's current market cap is $28B. |
| What is the current revenue of DexCom? | DexCom's last 12 months revenue is $5B. |
| What is the current revenue growth of DexCom? | DexCom revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of DexCom? | Current revenue multiple of DexCom is 5.8x. |
| Is DexCom profitable? | Yes, DexCom is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DexCom? | DexCom's last 12 months EBITDA is $1B. |
| What is DexCom's EBITDA margin? | DexCom's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of DexCom? | Current EBITDA multiple of DexCom is 19.6x. |
| What is the current FCF of DexCom? | DexCom's last 12 months FCF is $1B. |
| What is DexCom's FCF margin? | DexCom's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of DexCom? | Current FCF multiple of DexCom is 21.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.